Open access · OA
via OpenAlex
Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease
Circulation Research · 2021 · ▲ 686 citations
Abstract
IL (interleukin)-6 is a pivotal cytokine of innate immunity, which enacts a broad set of physiological functions traditionally associated with host defense, immune cell regulation, proliferation, and differentiation. Following recognition of innate immune pathways leading from the NLRP3 (NOD-, LRR-, and pyrin domain-containing protein 3) inflammasome to IL-1 to IL-6 and on to the hepatically derived clinical biomarker CRP (C-reactive protein), an expanding literature has led to understanding of the proatherogenic role for IL-6 in cardiovascular disease and thus the potential for IL-6 inhibition as a novel method for vascular protection. In this review, we provide an overview of the mechanisms by which IL-6 signaling occurs and how that impacts upon pharmacological inhibition; describe murine models of IL-6 and atherogenesis; summarize human epidemiological data outlining the utility of IL-6 as a biomarker of vascular risk; outline genetic data suggesting a causal role for IL-6 in systemic atherothrombosis and aneurysm formation; and then detail the potential role of IL-6 inhibition in stable coronary disease, acute coronary syndromes, heart failure, and the atherothrombotic complications associated with chronic kidney disease and end-stage renal failure. Finally, we review anti-inflammatory and antithrombotic findings for ziltivekimab, a novel IL-6 ligand inhibitor being developed specifically for use in atherosclerotic disease and poised to be tested formally in a large-scale cardiovascular outcomes trial focused on individuals with chronic kidney disease and elevated levels of CRP, a population at high residual atherothrombotic risk, high residual inflammatory risk, and considerable unmet clinical need.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1161/circresaha.121.319077
- Canonical
- link ↗
- Fetched
- 2026-07-28 MST
Cite this
APA
Ridker, P.M., & Rane, M. (2021). Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. <em>Circulation Research</em>. https://doi.org/10.1161/circresaha.121.319077
Vancouver
Ridker PM, Rane M. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. Circulation Research. 2021. doi:10.1161/circresaha.121.319077.
BibTeX
@article{paul2021Interl,
title = {Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease},
author = {Paul M. Ridker and Manas Rane},
journal = {Circulation Research},
year = {2021},
doi = {10.1161/circresaha.121.319077},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Current Heart Failure Reports 2025
Open access · CC-BY
Inflammatory Biomarkers in Heart Failure: Clinical Perspectives on hsCRP, IL-6 and Emerging Candidates
Cardiovascular Drugs and Therapy 2020
Open access · CC-BY
Therapeutic Potential of Senolytics in Cardiovascular Disease
African Journal of Biomedical Research 2026
Open access · CC-BY
Inflammaging in Cardiovascular Disease: Emerging Mechanisms and Therapeutic Perspectives
The Clinician 2021
Open access · CC-BY
Interleukin 6 in aging and age-related diseases
Frontiers in Immunology 2023
Open access · CC-BY
The emerging role of exosomes in innate immunity, diagnosis and therapy
Reviews in Medical Virology 2020
Citation only